1297139-24-2

Basic information

• Product Name: (4R)-3-[(2S,3S,4E)-3-hydroxy-5-phenyl-2-(2-propen-1-yl)-4-pentenoyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one
• Synonyms: (4R)-3-[(2S,3S,4E)-3-hydroxy-5-phenyl-2-(2-propen-1-yl)-4-pentenoyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one
• CAS NO: 1297139-24-2
• Molecular Weight: 391.467
• Mol File: 1297139-24-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (4R)-3-[(2S,3S,4E)-3-hydroxy-5-phenyl-2-(2-propen-1-yl)-4-pentenoyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4R)-3-[(2S,3S,4E)-3-hydroxy-5-phenyl-2-(2-propen-1-yl)-4-pentenoyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one(1297139-24-2)
• EPA Substance Registry System: (4R)-3-[(2S,3S,4E)-3-hydroxy-5-phenyl-2-(2-propen-1-yl)-4-pentenoyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one(1297139-24-2)

Safety Data

• Hazardous Substances Data: 1297139-24-2(Hazardous Substances Data)

Upstream product

• 14371-10-9 (E)-3-phenylpropenal 
• 155399-10-3 (4R)-3-(4-pentenoyl)-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 39716-58-0 pent-4-enoyl chloride 
• 591-80-0 pent-4-enoic acid 

Downstream Products

• 1431285-91-4 N₁-[(1S,2S,3E)-2-{[(1,1-dimethylethyl)(dimethyl)silyl] oxy}-4-phenyl-1-(2-propen-1-yl)-3-buten-1-yl]-N₂-[(4-nitrophenyl)sulfonyl]glycinamide 
• 1431285-87-8 (2S,3S,4E)-3-hydroxy-5-phenyl-2-(2-propen-1-yl)-4-pentenoic acid 
• 1431285-88-9 (4S,5S)-5-[(E)-2-phenylethenyl]-4-(2-propen-1-yl)-1,3-oxazolidin-2-one 
• 1431285-89-0 (1E,3S,4S)-4-amino-1-phenyl-1,6-heptadien-3-ol 
• 1431285-90-3 (1E,3S,4S)-3-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-1-phenyl-1,6-heptadien-4-amine 
• 1297140-21-6 1-[(1S,2S,3E)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-4-phenyl-1-(2-propen-1-yl)-3-buten-1-yl]-4-[(4-nitrophenyl)sulfonyl]-2-piperazinone 
• 1297140-20-5 1-[(1S,2S,3E)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-4-phenyl-1-(2-propen-1-yl)-3-buten-1-yl]-2-piperazinone 
• 1297140-23-8 4-{[3-chloro-5-cyclopropyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]carbonyl}-1-[(1S,2S,3E)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-4-phenyl-1-(2-propen-1-yl)-3-buten-1-yl]-2-piperazinone 
• 1297139-34-4 1-((1S,2S,3S,5S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}bicyclo[3.1.0]hex-3-yl)-4-[(4-nitrophenyl)sulfonyl]-2-piperazinone 
• 1297139-33-3 N₁-((1S,2S,3S,5S)-2-{[(1,1-dimethylethyl)(dimethyl) silyl]oxy}bicyclo [3.1.0]hex-3-yl)-N₂-[(4-nitrophenyl)sulfonyl]glycinamide 
• 1297139-27-5 (4R)-3-[((1S,2S,3S,5S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy} bicyclo[3.1.0]hex-3-yl)carbonyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 1297139-25-3 (4R)-3-{[(1S,2S,3S,5S)-2-hydroxybicyclo[3.1.0]hex-3-yl]carbonyl}-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 324741-99-3 (4R)-3-{[(1S,2S)-2-hydroxy-3-cyclopenten-1-yl]carbonyl}-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 1297139-59-3 4-{[3-chloro-5-cyclopropyl-7-(3-fluorophenyI)pyrazolo[1,5-a]pyridin-2-yl]carbonyl}-1-((1S,2S,3S,5S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}bicyclo[3.1.0]hex-3-yl)-2-piperazinone 

Relevant articles and documents

Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route

Stimulator of Interferon Genes (STING) plays an important role in innate immunity by inducing type I interferon production upon infection with intracellular pathogens. STING activation can promote increased T-cell activation and inflammation in the tumor microenvironment, resulting in antitumor immunity. Natural and synthetic cyclic dinucleotides (CDNs) are known to activate STING, and several synthetic CDN molecules are being investigated in the clinic using an intratumoral administration route. Here, we describe the identification of STING agonist 15a, a cyclic dinucleotide structurally diversified from natural ligands with optimized properties for systemic intravenous (iv) administration. Our studies have shown that STING activation by 15a leads to an acute innate immune response as measured by cytokine secretion and adaptive immune response via activation of CD8+ cytotoxic T-cells, which ultimately provides robust antitumor efficacy.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

BENZIMIDAZOLE ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).